{"id":534758,"date":"2021-09-07T08:04:34","date_gmt":"2021-09-07T12:04:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-07T08:04:34","modified_gmt":"2021-09-07T12:04:34","slug":"ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"
\n

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc.\u00a0(NASDAQ:\u00a0OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd<\/sup> Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT.<\/p>\n

A webcast of the virtual presentation will be available on the Events & Presentations section of the Company\u2019s website at investors.ovidrx.com<\/a>.<\/p>\n

\n About\u00a0Ovid Therapeutics <\/strong>\n <\/p>\n

Ovid Therapeutics Inc.\u00a0is a\u00a0New York-based biopharmaceutical company using its BoldMedicine\u00ae<\/sup>\u00a0approach to develop medicines that transform the lives of patients with neurological disorders.\u00a0Ovid\u00a0seeks to couple deep CNS experience with emerging advances in genetics and the pathways of the brain to build a leading, next-generation neuroscience pipeline. Ovid\u2019s current pipeline programs include: OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with\u00a0Tuberous Sclerosis Complex\u00a0and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorders; and other non-disclosed research targets. Additionally,\u00a0Ovid\u00a0maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Two Phase 3 trials for soticlestat in Dravet syndrome and Lennox-Gastaut syndrome are expected to begin in 2021. For more information on\u00a0Ovid, please visit\u00a0www.ovidrx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation, statements regarding the development of Ovid\u2019s product candidate pipeline and the clinical development of soticlestat. You can identify forward-looking statements because they contain words such as \u201cwill,\u201d \u201cappears,\u201d \u201cbelieves\u201d and \u201cexpects.\u201d Forward-looking statements are based on Ovid\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties in the development and regulatory approval processes. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid\u2019s filings with the Securities and Exchange Commission under the caption \u201cRisk Factors.\u201d Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid\u2019s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

\n Investors and Media<\/strong>:
Meg Alexander
Ovid Therapeutics Inc.
Investor Relations & Public Relations
917-943-6681
malexander@ovidrx.com<\/a>\u00a0<\/p>\n

OR<\/p>\n

\n Investors:<\/strong>
\n
Argot Partners
Dawn Schottlandt
212-600-1902
ovid@argotpartners.com<\/a>\u00a0<\/p>\n

\n Media:<\/strong>
\n
Dan Budwick
1AB
dan@1abmedia.com<\/a>\u00a0<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc.\u00a0(NASDAQ:\u00a0OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT. A webcast of the virtual presentation will be available on the Events & Presentations section of the Company\u2019s website at investors.ovidrx.com. About\u00a0Ovid Therapeutics Ovid Therapeutics Inc.\u00a0is a\u00a0New York-based biopharmaceutical company using its BoldMedicine\u00ae\u00a0approach to develop medicines that transform the lives of patients with neurological disorders.\u00a0Ovid\u00a0seeks to couple deep CNS experience with emerging advances in genetics and … <\/p>\n

Continue reading “Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534758","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOvid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc.\u00a0(NASDAQ:\u00a0OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT. A webcast of the virtual presentation will be available on the Events & Presentations section of the Company\u2019s website at investors.ovidrx.com. About\u00a0Ovid Therapeutics Ovid Therapeutics Inc.\u00a0is a\u00a0New York-based biopharmaceutical company using its BoldMedicine\u00ae\u00a0approach to develop medicines that transform the lives of patients with neurological disorders.\u00a0Ovid\u00a0seeks to couple deep CNS experience with emerging advances in genetics and … Continue reading "Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T12:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-07T12:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":494,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=\",\"datePublished\":\"2021-09-07T12:04:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc.\u00a0(NASDAQ:\u00a0OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT. A webcast of the virtual presentation will be available on the Events & Presentations section of the Company\u2019s website at investors.ovidrx.com. About\u00a0Ovid Therapeutics Ovid Therapeutics Inc.\u00a0is a\u00a0New York-based biopharmaceutical company using its BoldMedicine\u00ae\u00a0approach to develop medicines that transform the lives of patients with neurological disorders.\u00a0Ovid\u00a0seeks to couple deep CNS experience with emerging advances in genetics and … Continue reading \"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T12:04:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-07T12:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":494,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=","datePublished":"2021-09-07T12:04:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDk1NCM0MzkxMTE0IzIwNzAyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534758"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534758\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}